Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
AUPH
AUPH
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
AUPH News
Reasons to Consider Aurinia Pharmaceuticals (AUPH) as a Strong Momentum Stock: Is It Time to Buy?
Dec 05 2025
NASDAQ.COM
Examining Aurinia Pharmaceuticals (NasdaqGM:AUPH) Valuation Following Recent Increase in Share Price
Nov 30 2025
Yahoo Finance
Inaugural Week of AUPH Options Trading for July 2026
Nov 24 2025
NASDAQ.COM
Aurinia Pharmaceuticals Stock Increases Following Jefferies Upgrade
Nov 07 2025
Yahoo Finance
Editorial | The FDA's Crisis Intensifies
Nov 06 2025
WSJ
Analysis | Democrats Shine in the Evening
Nov 05 2025
WSJ
Aurinia Pharmaceuticals Shares Rise 7% Following Strong Q3 Revenue and Upgraded Forecast
Nov 04 2025
NASDAQ.COM
Aurinia Pharma Reports Surge in Q3 Earnings; Pre-market Stock Rises and Annual Forecast Upgraded
Nov 04 2025
NASDAQ.COM
Aurinia Pharmaceuticals Announces Financial Results for Q3 and Year-to-Date Ending September 30, 2025, Along with Recent Business Developments
Nov 04 2025
Newsfilter
FDA Drug Chief George Tidmarsh Steps Down Amid Misuse of Power Allegations
Nov 03 2025
Benzinga
FDA Official Resigns Amid Lawsuit from Pharmaceutical Company
Nov 03 2025
WSJ
High-ranking FDA official Tidmarsh steps down following remarks on kidney medication and HHS investigation.
Nov 02 2025
SeekingAlpha
Aurinia Pharmaceuticals Achieves Analyst Price Target
Oct 21 2025
NASDAQ.COM
Aurinia Reacts to Remarks from Senior FDA Official Regarding Key Drug
Sep 30 2025
SeekingAlpha
Biotech Stocks Surge in After-Hours Trading Following Trial Advancements and Important Announcements
Sep 30 2025
NASDAQ.COM
Aurinia Pharma Confirms Safety and Efficacy of LUPKYNIS After FDA Official's Retraction
Sep 30 2025
NASDAQ.COM
Show More News
